Antipsychotic compound
Pharmaceutical compound
Dexclamol (AY 24169) was an investigational new drug developed by McKenna and Harrison, Ltd. that was evaluated as a antipsychotic.[1][2][3][4] It acts as a dopamine receptor antagonist.[1]
See also
References
- ^ a b Humber LG, Bruderlein FT, Voith K (November 1975). “Neuroleptic agents of the benzocycloheptapyridoisoquinoline series. A hypothesis on their mode of interaction with the central dopamine receptor”. Molecular Pharmacology. 11 (6): 833–840. doi:10.1016/S0026-895X(25)10694-9. PMID 1239657.
- ^ Elks J, Ganellin CR, eds. (1990). Dictionary of Drugs. Springer US. doi:10.1007/978-1-4757-2085-3. ISBN 978-1-4757-2087-7.
- ^ Castañer J, Paton DM (1976). “Dexclamol hydrochloride”. Drugs of the Future. 1 (8): 366. doi:10.1358/dof.1976.001.08.1002521.
- ^ US 3657250, Bruderlein FT, Humber LG, ”Benzocycloheptaisoquinoline derivatives”, assigned to Ayerst Mckenna and Harrison Inc.
| σ1 |
|
|---|---|
| σ2 |
|
| Unsorted |
|
See also: Receptor/signaling modulators | |
| Classes | |
|---|---|
| Antidepressants (a.k.a. TCAsTooltip tricyclic antidepressant) |
|
| Antihistamines |
|
| Antipsychotics |
|
| Anticonvulsants | |
| Anticholinergics | |
| Others | |